Alnylams ALN-VSP Phase I trial data on liver tumor presented at ASCO 2011 Alnylam Pharmaceuticals.

We believe the results from our ALN-VSP Phase I trial represent a significant milestone in the advancement of RNAi therapeutics. Certainly, our data demonstrate for the first time both medical activity and RNAi system for an RNAi therapeutic, said John Maraganore, Ph.D., CEO of Alnylam. Obviously, these data aren’t only very important to the continued advancement of our ALN-VSP program, but they also significantly boost our confidence in our whole pipeline of systemically delivered RNAi therapeutics, including ALN-TTR01 which is normally in a Phase I study for the treating transthyretin mediated amyloidosis, and ALN-PCS, that will soon enter clinical trials for the treating severe hypercholesterolemia.Related StoriesNew UCLA study talks about primary care medical house in reducing childrens' repeat appointments to hospitalsStudy: Post hospital syndrome is usually significant risk element for individuals undergoing elective surgeryFirst hospital installs Ortho Vision Analyzer’Our CHOP Laboratories have become proud to, once again, receive accreditation from the faculty of American Pathologists,’ stated Robert W. Doms, M.D., Ph.D., Pathologist-in-Chief at The Kids's Hospital of Philadelphia. ‘The clinical diagnostic testing that happens within this section is actually revolutionizing medicine, offering hope to the sickest of children suffering from uncommon pediatric disease.